secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2025-02-10T23:59:59+00:00
Accession:  0000950170-25-017035
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta Q1 net loss narrows to $22.3M; RSV Phase 2 topline data due Q3 2025
--------------------------------------------------------------------------

- Net loss $22.3M (-$1.05/sh) vs loss $33.4M (-$1.58/sh) YoY; revenue $17M from MAVYRET royalties.
- Cash & securities $216.7M; expects runway into FY2028.
- RSV zelicapavir Phase 2 RSVHR top-line data expected Q3 2025; Dec 2024 pediatric study showed antiviral effect.
- Immunology: EPS-1421 KIT inhibitor IND studies ongoing; STAT6 candidate selection H2 2025; third program announced 2025.
- Filed appeal in patent lawsuit against Pfizer over Paxlovid (Feb 3, 2025).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000095017025017035/0000950170-25-017035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000095017025017035/enta-20250210.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-017035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer